Biomea Fusion/$BMEA
1D1W1MYTD1Y5YMAX
About Biomea Fusion
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
- Ticker
- $BMEA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 37
- Headquarters
- San Carlos, United States
- Website
- biomeafusion.com
Biomea Fusion Metrics
BasicAdvanced
$125M
-
-$0.47
-0.30
-
Price and volume
Market cap
$125M
Beta
-0.3
52-week high
$2.99
52-week low
$0.87
Average daily volume
1.2M
Financial strength
Current ratio
3.475
Quick ratio
3.322
Total debt to equity
7.226
Profitability
EBITDA (TTM)
-55.319
Management effectiveness
Return on assets (TTM)
-63.46%
Return on equity (TTM)
-164.14%
Valuation
Price to book
10.33
Price to tangible book (TTM)
10.33
Price to free cash flow (TTM)
-2.532
Free cash flow yield (TTM)
-39.49%
Free cash flow per share (TTM)
-0.683
Growth
Earnings per share change (TTM)
-84.26%
3-year earnings per share growth (CAGR)
-47.75%
What the Analysts think about Biomea Fusion
Analyst ratings (Buy, Hold, Sell) for Biomea Fusion stock.
Biomea Fusion Financial Performance
Revenues and expenses
Biomea Fusion Earnings Performance
Company profitability
Biomea Fusion News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.